{"id":"daclizumab-or-basiliximab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs bind to CD25, the alpha subunit of the high-affinity IL-2 receptor expressed on activated T lymphocytes. By blocking IL-2 signaling, they suppress T cell-mediated immune responses. Daclizumab is a humanized antibody while Basiliximab is a chimeric antibody; both are used as immunosuppressants in transplantation and autoimmune conditions.","oneSentence":"Daclizumab and Basiliximab are monoclonal antibodies that block the IL-2 receptor (CD25) on T cells, preventing T cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:41.151Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in renal transplantation (Basiliximab approved)"},{"name":"Multiple sclerosis (Daclizumab in development/phase 3)"},{"name":"Autoimmune hepatitis and other autoimmune conditions (investigational)"}]},"trialDetails":[{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT00468117","phase":"PHASE3","title":"Efficacy of Islet After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-01","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00859131","phase":"NA","title":"Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":"End Stage Renal Disease","enrollment":200},{"nctId":"NCT02694770","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Neihulizumab vs \"Conventional Treatment\" to Treat Sr-aGvHD","status":"WITHDRAWN","sponsor":"AbGenomics B.V Taiwan Branch","startDate":"2016-07","conditions":"Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation","enrollment":""},{"nctId":"NCT00434850","phase":"PHASE2","title":"Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Diabetes Mellitus, Type 1","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2675,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Daclizumab or Basiliximab","genericName":"Daclizumab or Basiliximab","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"Daclizumab and Basiliximab are monoclonal antibodies that block the IL-2 receptor (CD25) on T cells, preventing T cell activation and proliferation. Used for Prevention of acute organ rejection in renal transplantation (Basiliximab approved), Multiple sclerosis (Daclizumab in development/phase 3), Autoimmune hepatitis and other autoimmune conditions (investigational).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}